Literature DB >> 1628089

Effects of long term octreotide on gall stone formation and gall bladder function.

G W Bigg-Wither1, K K Ho, R R Grunstein, C E Sullivan, B D Doust.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1628089      PMCID： PMC1881991          DOI： 10.1136/bmj.304.6842.1611

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group.

Authors:  G Sassolas; A G Harris; A James-Deidier
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

2.  Sonographic measurement of gallbladder volume.

Authors:  W J Dodds; W J Groh; R M Darweesh; T L Lawson; S M Kishk; M K Kern
Journal:  AJR Am J Roentgenol       Date:  1985-11       Impact factor: 3.959

3.  Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.

Authors:  K Y Ho; A J Weissberger; P Marbach; L Lazarus
Journal:  Ann Intern Med       Date:  1990-02-01       Impact factor: 25.391

4.  Why does somatostatin cause gallstones?

Authors:  S A Ahrendt; G E McGuire; H A Pitt; K D Lillemoe
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

5.  Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly.

Authors:  P A van Liessum; W P Hopman; G F Pieters; J B Jansen; A G Smals; G Rosenbusch; P W Kloppenborg; C B Lamers
Journal:  J Clin Endocrinol Metab       Date:  1989-09       Impact factor: 5.958
  5 in total
  12 in total

1.  Gall stones induced by octreotide.

Authors:  S M Catnach; J A Wass; J V Anderson; M Besser; P Fairclough; H Hussaini; H Dowling
Journal:  BMJ       Date:  1992-08-01

Review 2.  Treatment options in acromegaly. Benefits and costs.

Authors:  L M Weekes; K K Ho; J P Seale
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

3.  Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda Page; David R Holmes; Xujian Li; Eric J Bergstralh; Maria V Irazabal; Bohyun Kim; Bernard F King; James F Glockner; Nicholas F Larusso; Vicente E Torres
Journal:  Nephrol Dial Transplant       Date:  2012-07-06       Impact factor: 5.992

4.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda J Page; Vickie J Kubly; Eric J Bergstralh; Xujian Li; Bohyun Kim; Bernard F King; James Glockner; David R Holmes; Sandro Rossetti; Peter C Harris; Nicholas F LaRusso; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

Review 5.  Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century?

Authors:  Eldon A Shaffer
Journal:  Curr Gastroenterol Rep       Date:  2005-05

6.  Biliary Tract and Liver Complications in Polycystic Kidney Disease.

Authors:  Parminder K Judge; Charlie H S Harper; Benjamin C Storey; Richard Haynes; Martin J Wilcock; Natalie Staplin; Raph Goldacre; Colin Baigent; Jane Collier; Michael Goldacre; Martin J Landray; Christopher G Winearls; William G Herrington
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

7.  Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.

Authors:  S H Hussaini; S P Pereira; M J Veysey; C Kennedy; P Jenkins; G M Murphy; J A Wass; R H Dowling
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

8.  Low serum levels of ghrelin are associated with gallstone disease.

Authors:  Nahum Mendez-Sanchez; Guadalupe Ponciano-Rodriguez; Luisa Bermejo-Martinez; Antonio-R Villa; Norberto-C Chavez-Tapia; Daniel Zamora-Valdes; Raul Pichardo-Bahena; Blanca Barredo-Prieto; Martha-H Uribe-Ramos; Martha-H Ramos; Hector A Baptista-Gonzalez; Misael Uribe
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

Review 9.  Rare cystic liver lesions: a diagnostic and managing challenge.

Authors:  Andreas Bakoyiannis; Spiros Delis; Charina Triantopoulou; Christos Dervenis
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

10.  Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA.

Authors:  James A Martenson; Michele Y Halyard; Jeff A Sloan; Gary M Proulx; Robert C Miller; Richard L Deming; Stephen J Dick; Harold A Johnson; T H Patricia Tai; Angela W Zhu; Joan Keit; Kathy J Stien; Pamela J Atherton
Journal:  J Clin Oncol       Date:  2008-09-02       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.